DIAMOND BIOFUND INC (6901) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has a cash flow conversion efficiency ratio of -0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-21.12 Million ≈ $-665.27K USD) by net assets (NT$9.22 Billion ≈ $290.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See DIAMOND BIOFUND INC net asset quality index to measure how much of total assets are equity-financed.
DIAMOND BIOFUND INC - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how DIAMOND BIOFUND INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of DIAMOND BIOFUND INC to evaluate the quality of earnings relative to operating cash generation.
DIAMOND BIOFUND INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DIAMOND BIOFUND INC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ranpak Holdings Corp
NYSE:PACK
|
0.008x |
|
TARC Limited
NSE:TARC
|
0.245x |
|
VALNEVA SE SP.ADS/2
F:AYJ0
|
-0.231x |
|
Antofagasta PLC
LSE:ANTO
|
0.043x |
|
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
|
0.058x |
|
IntelliEPI Cayman
TWO:4971
|
0.031x |
|
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
|
0.002x |
|
Hanssem
KO:009240
|
0.096x |
Annual Cash Flow Conversion Efficiency for DIAMOND BIOFUND INC (2019–2025)
The table below shows the annual cash flow conversion efficiency of DIAMOND BIOFUND INC from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see how much is DIAMOND BIOFUND INC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$9.22 Billion ≈ $290.51 Million |
NT$-165.92 Million ≈ $-5.23 Million |
-0.018x | -116.39% |
| 2024-12-31 | NT$10.37 Billion ≈ $326.81 Million |
NT$1.14 Billion ≈ $35.89 Million |
0.110x | +821.33% |
| 2023-12-31 | NT$12.86 Billion ≈ $405.22 Million |
NT$-195.82 Million ≈ $-6.17 Million |
-0.015x | -135.56% |
| 2022-12-31 | NT$11.05 Billion ≈ $348.15 Million |
NT$473.09 Million ≈ $14.90 Million |
0.043x | +248.09% |
| 2021-12-31 | NT$10.39 Billion ≈ $327.41 Million |
NT$-300.42 Million ≈ $-9.46 Million |
-0.029x | -260.45% |
| 2020-12-31 | NT$9.10 Billion ≈ $286.71 Million |
NT$-72.99 Million ≈ $-2.30 Million |
-0.008x | +38.98% |
| 2019-12-31 | NT$3.01 Billion ≈ $94.85 Million |
NT$-39.57 Million ≈ $-1.25 Million |
-0.013x | -- |
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.